Insulet (Nasdaq:PODD) announced today that the FDA cleared its Omnipod 5 automated insulin delivery for use by people with type 2 diabetes. Clearance makes Omnipod 5, the company’s latest-generation AID system, the first and only such system cleared for type 1 and type 2 diabetes. Its indication covers those ages 18 and older in the […]
Insulet
Former Medtronic acquisition target EOFlow to raise $61.5M, faces Insulet patent infringement lawsuit
EOFlow faces a patent infringement lawsuit from fellow insulin patch pump maker Insulet as it attempts to bring in millions in a new funding round. The Korea-based company develops the EOPatch — a tubeless, wearable and fully disposable insulin delivery device. EOFlow was at one point set to be acquired by Medtronic for $738 million last […]
The 9 largest diabetes technology companies in the world
Diabetes technology comes in all shapes and sizes: insulin delivery systems, continuous glucose monitors and more. The companies that develop these technologies come in all shapes and sizes, too. Some focus entirely (or almost entirely) on solutions for people with diabetes. Others are much larger medtech firms that still have sizable business units that focus […]
Insulet opens new manufacturing plant in Malaysia
Insulet (Nasdaq:PODD) announced today that it commenced the grand opening of its new manufacturing facility in Johor Bahru, Malaysia. The Acton, Massachusetts-based company first broke ground on the plant in June 2022. It strengthens the company’s global operational capabilities and supply chain resiliency with expanded Omnipod automated insulin delivery system manufacturing. Insulet said the 400,000-square-foot […]
Insulet reports Omnipod sales growth of 26% in Q2, raises guidance despite EPS miss
Insulet (Nasdaq:PODD) stock is down on second-quarter results that came in mixed compared to the consensus forecast. Shares of PODD were down more than 7% to $184.56 apiece by midday trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up slightly. Yesterday evening, the Acton, […]
Insulet preliminary Q2 revenue report beats The Street
Insulet (Nasdaq: PODD) saw its revenue increase 23% year-over-year to $488 million in the second quarter, which ended June 30. That’s according to preliminary Q2 revenue numbers that Insulet released today. The result beats the consensus of Wall Street analysts, who expected that Insulet had $460.27 million in revenue in Q2. The maker of Omnipod […]
The biggest stories from the American Diabetes Association (ADA) 2024 Scientific Sessions
The American Diabetes Association took to Orlando, Florida, the past few days for its 84th Scientific Sessions as optimism grows over diabetes tech. Topics covered included expanding technologies to the type 2 diabetes population (90% of people with diabetes), GLP-1 drugs, automation, broadening user bases and more. The usual big-hitters stepped up to the plate […]
Insulet seeks expanded FDA nod for Omnipod 5 to include type 2 population, reports positive data
Insulet (Nasdaq:PODD) today announced positive results from a type 2 diabetes pivotal trial of its Omnipod 5 automated insulin delivery system. The company recently submitted its study results to the FDA for an expansion of Omnipod 5’s indications for use. It hopes to garner clearance for the type 2 diabetes population and launch in the […]
Insulet fully launches Omnipod 5 with Dexcom G7 in the U.S. along with iPhone app
Insulet (Nasdaq:PODD) announced today that it began a full U.S. launch of Omnipod 5 with the Dexcom G7 continuous glucose monitor (CGM). The company also announced a series of launches and updates, including a limited release of the Omnipod 5 App for iPhone. Insulet also made Omnipod 5 available in France and launched the system […]
Insulet sales are up 23% but Q1 EPS misses Wall Street forecast
Insulet (Nasdaq:PODD) shares fell after hours today on first-quarter results that came in mixed compared to the consensus forecast. Shares of PODD dipped 3% to $172 apiece in after the market closed today. The Acton, Massachusetts-based automated insulin delivery technology developer reported profits of $51.5 million. That equals 73¢ per share on sales of $441.7 […]
